Inhibin A is a maternal serum marker for Down's syndrome early in the first trimester

被引:14
作者
Christiansen, M [1 ]
Norgaard-Pedersen, B [1 ]
机构
[1] Statens Serum Inst, Dept Clin Biochem, DK-2300 Copenhagen, Denmark
关键词
first-trimester screening; free beta-form of human chorionic gonadotrophin; Monte Carlo simulation; pregnancy-associated plasma protein-A;
D O I
10.1111/j.1399-0004.2005.00441.x
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Inhibin A is a maternal serum marker for fetal Down's syndrome (DS) in the second trimester. We examined whether inhibin A could be used early in the first trimester. Maternal serum concentrations of inhibin A were determined in 81 controls and 27 cases of fetal trisomy 21 in gestational week 5-11. The log MoM (Multiple of the Median of normal pregnancies) inhibin A concentration in DS pregnancies increased with gestational age (p = 0.001) from a mean log MoM (standard deviation) of -0.1754 (0.3712) (n = 11) in week 7-8 to a mean log MoM (standard deviation) of 0.1842 (0.2145) (n = 12) in week 9-11. This corresponded to an increase in inhibin median MoM from 0.67 to 1.53. When inhibin A was used together with pregnancy-associated plasma protein-A, free beta-human chorionic gonadotrophin and nuchal translucency as DS markers, the estimated detection rates were 81.4 and 82.6% in weeks 7-8 and 9-11, respectively, for false-positive rates of 0.9 and 1.0%. The performance of the latter combination early in the first trimester is nearly as good as that of integrated first- and second-trimester screening, with the further advantage that the risk can be reported to the pregnant woman in first trimester.
引用
收藏
页码:35 / 39
页数:5
相关论文
共 39 条
[1]   Dimeric inhibin a as a marker for Down's syndrome in early pregnancy [J].
Aitken, DA ;
Wallace, EM ;
Crossley, JA ;
Swanston, IA ;
vanPareren, Y ;
vanMaarle, M ;
Groome, NP ;
Macri, JN ;
Connor, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (19) :1231-1236
[2]   Screening for Down's syndrome: Changes in marker levels and detection rates between first and second trimesters [J].
Berry, E ;
Aitken, DA ;
Crossley, JA ;
Macri, JN ;
Connor, JM .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1997, 104 (07) :811-817
[3]  
Christiansen M, 1999, PRENATAL DIAG, V19, P905, DOI 10.1002/(SICI)1097-0223(199910)19:10<905::AID-PD658>3.0.CO
[4]  
2-Q
[5]   Screening for Down's syndrome in early and late first and second trimester using six maternal serum markers [J].
Christiansen, M ;
Larsen, SO ;
Oxvig, C ;
Qin, QP ;
Wagner, JM ;
Overgaard, MT ;
Gleich, GJ ;
Sottrup-Jensen, L ;
Norgaard-Pedersen, B .
CLINICAL GENETICS, 2004, 65 (01) :11-16
[6]  
Cuckle HS, 1999, PRENATAL DIAG, V19, P505, DOI 10.1002/(SICI)1097-0223(199906)19:6<505::AID-PD572>3.0.CO
[7]  
2-6
[8]  
Cuckle HS, 1996, PRENATAL DIAG, V16, P1095
[9]   Placental and maternal serum inhibin-A and activin-A levels in Down's syndrome pregnancies [J].
Dalgliesh, GL ;
Aitken, DA ;
Lyall, F ;
Howatson, AG ;
Conner, JM .
PLACENTA, 2001, 22 (2-3) :227-234
[10]   IMMUNOASSAYS FOR INHIBIN AND ITS SUBUNITS - FURTHER APPLICATIONS OF THE SYNTHETIC PEPTIDE APPROACH [J].
GROOME, N ;
OBRIEN, M .
JOURNAL OF IMMUNOLOGICAL METHODS, 1993, 165 (02) :167-176